SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
MP Sormani, I Schiavetti, D Landi… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Multiple Sclerosis Journal, 2022•journals.sagepub.com
Background: The MuSC-19 project is an Italian cohort study open to international partners
that collects data on multiple sclerosis (MS) patients with COVID-19. During the second
wave of the pandemic, serological tests became routinely available. Objective: To evaluate
the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-
modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had
undergone a serological test. Methods: We evaluated the association between positive …
that collects data on multiple sclerosis (MS) patients with COVID-19. During the second
wave of the pandemic, serological tests became routinely available. Objective: To evaluate
the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-
modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had
undergone a serological test. Methods: We evaluated the association between positive …
Background
The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available.
Objective
To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test.
Methods
We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model.
Results
Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002).
Conclusion
Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.
Sage Journals